BACKGROUND: Preliminary data suggest that pegfilgrastim given on day 4 (P4) might be superior to pegfilgrastim on day 2 (P2) in reducing grade 4 leucopenia. METHODS:Patients with node-positive primary breast cancer receivingepirubicin-paclitaxel-cyclophosphamide chemotherapy were randomized to receive P2 versus P4. Primary endpoint was leucopenia grade 4, assuming a risk reduction of 50% with P4 from 50% in P2 to 25% with P4. RESULTS:Three-hundred fifty-one patients were randomized to P2 (n = 174) versus P4 (n = 177). The rate of leucopenia (grade 4) was 47.1% with P2 and 42.0% with P4 (p = 0.387), neutropenia (grade 3 + 4) was 47.9% versus 40.8% (p = 0.337), FN was 4.7% versus 8.0% (p = 0.271), and infections was 29.9% versus 25.4% (p = 0.404), respectively. CONCLUSION: This study failed to demonstrate that pegfilgrastim on day 4 was more efficacious than on day 2 with respect to grade 4 leucopenia (the primary endpoint), febrile neutropenia, or infections.
RCT Entities:
BACKGROUND: Preliminary data suggest that pegfilgrastim given on day 4 (P4) might be superior to pegfilgrastim on day 2 (P2) in reducing grade 4 leucopenia. METHODS:Patients with node-positive primary breast cancer receiving epirubicin-paclitaxel-cyclophosphamide chemotherapy were randomized to receive P2 versus P4. Primary endpoint was leucopenia grade 4, assuming a risk reduction of 50% with P4 from 50% in P2 to 25% with P4. RESULTS: Three-hundred fifty-one patients were randomized to P2 (n = 174) versus P4 (n = 177). The rate of leucopenia (grade 4) was 47.1% with P2 and 42.0% with P4 (p = 0.387), neutropenia (grade 3 + 4) was 47.9% versus 40.8% (p = 0.337), FN was 4.7% versus 8.0% (p = 0.271), and infections was 29.9% versus 25.4% (p = 0.404), respectively. CONCLUSION: This study failed to demonstrate that pegfilgrastim on day 4 was more efficacious than on day 2 with respect to grade 4 leucopenia (the primary endpoint), febrile neutropenia, or infections.
Authors: M S Aapro; D A Cameron; R Pettengell; J Bohlius; J Crawford; M Ellis; N Kearney; G H Lyman; V C Tjan-Heijnen; J Walewski; D C Weber; C Zielinski Journal: Eur J Cancer Date: 2006-06-05 Impact factor: 9.162
Authors: M D Green; H Koelbl; J Baselga; A Galid; V Guillem; P Gascon; S Siena; R I Lalisang; H Samonigg; M R Clemens; V Zani; B C Liang; J Renwick; M J Piccart Journal: Ann Oncol Date: 2003-01 Impact factor: 32.976
Authors: F A Holmes; J A O'Shaughnessy; S Vukelja; S E Jones; J Shogan; M Savin; J Glaspy; M Moore; L Meza; I Wiznitzer; T A Neumann; L R Hill; B C Liang Journal: J Clin Oncol Date: 2002-02-01 Impact factor: 44.544
Authors: E Johnston; J Crawford; S Blackwell; T Bjurstrom; P Lockbaum; L Roskos; B B Yang; S Gardner; M A Miller-Messana; D Shoemaker; J Garst; G Schwab Journal: J Clin Oncol Date: 2000-07 Impact factor: 44.544
Authors: J M Vose; M Crump; H Lazarus; C Emmanouilides; D Schenkein; J Moore; S Frankel; I Flinn; W Lovelace; J Hackett; B C Liang Journal: J Clin Oncol Date: 2003-02-01 Impact factor: 44.544
Authors: G von Minckwitz; M Schwenkglenks; T Skacel; G H Lyman; A Lopez Pousa; P Bacon; V Easton; M S Aapro Journal: Eur J Cancer Date: 2008-12-26 Impact factor: 9.162
Authors: Jenny M Whitworth; Kellie S Matthews; Kimberly A Shipman; T Michael Numnum; James E Kendrick; Larry C Kilgore; J Michael Straughn Journal: Gynecol Oncol Date: 2008-12-24 Impact factor: 5.482
Authors: G von Minckwitz; S Kümmel; A du Bois; W Eiermann; H Eidtmann; B Gerber; J Hilfrich; J Huober; S D Costa; C Jackisch; S-T Grasshoff; S Vescia; T Skacel; S Loibl; K M Mehta; M Kaufmann Journal: Ann Oncol Date: 2007-09-09 Impact factor: 32.976
Authors: Sibylle Loibl; Tomas Skacel; Valentina Nekljudova; Hans Joachim Lück; Matthias Schwenkglenks; Thomas Brodowicz; Christoph Zielinski; Gunter von Minckwitz Journal: BMC Cancer Date: 2011-04-12 Impact factor: 4.430
Authors: Xinrong Guo; Sibylle Loibl; Michael Untch; Volker Möbus; Kathrin Schwedler; Peter A Fasching; Jana Barinoff; Frank Holms; Christoph Thomssen; Dirk M Zahm; Rolf Kreienberg; Maik Hauschild; Holger Eidtmann; Sascha Tauchert; Keyur Mehta; Gunter von Minckwitz Journal: Breast Care (Basel) Date: 2011-08-19 Impact factor: 2.860
Authors: Matteo Lambertini; Paolo Bruzzi; Francesca Poggio; Simona Pastorino; Giovanni Gardin; Matteo Clavarezza; Claudia Bighin; Paolo Pronzato; Lucia Del Mastro Journal: Support Care Cancer Date: 2015-08-27 Impact factor: 3.603
Authors: Alena M Pfeil; Kim Allcott; Ruth Pettengell; Gunter von Minckwitz; Matthias Schwenkglenks; Zsolt Szabo Journal: Support Care Cancer Date: 2014-10-07 Impact factor: 3.603
Authors: K Krzemieniecki; P Sevelda; F Erdkamp; M Smakal; M Schwenkglenks; J Puertas; A Trojan; Z Szabo; K Bendall; J Maenpaa Journal: Support Care Cancer Date: 2013-10-24 Impact factor: 3.603
Authors: Sibylle Schirm; Christoph Engel; Sibylle Loibl; Markus Loeffler; Markus Scholz Journal: J Cancer Res Clin Oncol Date: 2017-11-04 Impact factor: 4.553